

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10551151
	Filing Date		2006-05-08
	First Named Inventor	George C. Prendergast	
	Art Unit	1628	
	Examiner Name	Christopher Stone	
	Attorney Docket Number	3882-P03161US2	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1444935	CN	A	2003-10-01	East China University of Technology		<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10551151
Filing Date	2006-05-08
First Named Inventor	George C. Prendergast
Art Unit	1628
Examiner Name	Christopher Stone
Attorney Docket Number	3882-P03161US2

1	SUGANUMA et al., "Synergistic Effects of (-)-Epigallocatechin Gallate with (-)-Epicatechin, Sulindac, or Tamoxifen on Cancer-preventive Activity in the Human Lung Cancer Cell Line PC-9," Cancer Research (1999) 59:44-47	<input type="checkbox"/>
2	MASUDA et al., "Effects of Epigallocatechin-3-gallate on Growth, Epidermal Growth Factor Receptor Signaling Pathways, Gene Expression, and Chemosensitivity in Human Head and Neck Squamous Cell Carcinoma Cell Lines," Clinical Cancer Research (2001) 7:4220-4229	<input type="checkbox"/>
3	DAI et al., "Potentiation of Antitumor Effect Induced by Cytosine Arabinoside with (-)-Epigallocatechin-3-gallate in HL-60 Cells," Chinese Hospital Pharmacy Journal (2002) 22:458-461	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Christopher Stone/	Date Considered	05/27/2010
--------------------	---------------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.